Shandong Boan Biotechnology Co., Ltd. (6955.HK)
| Previous close | 10.600 |
| Open | 10.260 |
| Bid | 10.320 x N/A |
| Ask | 11.960 x N/A |
| Day's range | 10.220 - 10.940 |
| 52-week range | 9.290 - 24.200 |
| Volume | |
| Avg. volume | 269,572 |
| Market cap | 5.256B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.250 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.51 |
PR NewswireBoan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA
Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of pancreatic cancer by the U.S. Food and Drug Administration (FDA): one is BA1105, an innovative antibody; and the other is BA1301, an innovative Antibody-Drug Conjugate (ADC).
PR NewswireFirst Patient Enrolled in Phase III Clinical Trial of Boan Biotech's Nivolumab Injection
Boan Biotech (6955.HK) announced today that the first patient in Phase III clinical trial of its Nivolumab Injection (BA1104) in China has been enrolled. BA1104 is the first biosimilar to Opdivo® to undergo a Phase III study in China.
PR NewswireBoan Biotech's BA1202 Approved for Clinical Trial
Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been approved for a clinical trial by the Center for Drug Evaluation of China's National Medical Products Administration (NMPA). BA1202 is the first CEA/CD3 bispecific antibody approved for a clinical trial in China.
